CASI Pharmaceuticals Reports Substantial FY GAAP EPS Loss and Revenue Drop in Latest Update
Thursday, 28 March 2024, 11:22
CASI Pharmaceuticals Financial Results
In their recent press release, CASI Pharmaceuticals revealed their financial performance for the fiscal year.
Highlights:
- GAAP EPS: CASI Pharmaceuticals reported a substantial loss of $2.02 per share.
- Revenue: The company's revenue stood at $33.88M, marking a 21.4% year-over-year decrease.
The figures indicate a challenging year for CASI Pharmaceuticals, with a significant decline in both earnings per share and revenue, reflecting potential issues within the company.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.